Jim Greenwood

Jim Greenwood, Josh Boger - BIO 2008

IT Conversations (Free subscription) | 07/10/2008

On BioTech Nation, Dr. Moira Gunn speaks with BIO's Jim Greenwood, and Josh Boger from Vertex Pharmaceuticals during the anual International BIO Conference 2008.

New Rules On Generic Biological Medicines Under US Congressional Debate

Intellectual Property Watch (Free subscription) | 07/17/2008

By Liza Porteus Viana for Intellectual Property Watch When Biotechnology Industry Organization CEO Jim Greenwood meets with members of the United States Congress to talk to them about follow-on biologics, he brings a graphic model of an aspirin and a DVD showing the complex molecules of a biologic drug. He uses ...

BIO Welcomes PhRMA's Revised Code On Interactions With Healthcare Professionals

Medical News Today (Free subscription) | 07/11/2008

BIO President and CEO Jim Greenwood issued the following statement following the release of the Pharmaceutical Research and Manufacturers of America (PhRMA) revised Code on Interactions with Healthcare Professionals: "As public dialogue continues over the proper ethical standards guiding interac

BIO Welcomes PhRMA's Revised Code on Interactions with Healthcare Professionals

Business Wire (Free subscription) | 07/10/2008

WASHINGTON--(BUSINESS WIRE)--BIO President and CEO Jim Greenwood issued the following statement today following the release of the Pharmaceutical Research and Manufacturers of America

BIO to Co-Sponsor Import Safety Summit

Business Wire (Free subscription) | 07/02/2008

... public-private partnerships to further improve import safety,” stated BIO President and CEO Jim Greenwood. “BIO and our member companies remain committed to working with the Food and Drug Administration to better assure the safety, purity and potency of imported drugs and biologics. The continuing safety of our products for the patients we serve is our top priority.” The summit will feature...

CBO Savings Estimate For Follow-On Biologics Underscores Need For Congress To Move Quickly To Create Pathway For Follow-On Biologics

Medical News Today (Free subscription) | 06/27/2008

Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the Congressional Budget Office (CBO) report issued projecting cost savings from S.

CBO Savings Estimate for Follow-On Biologics Underscores Need for Congress to Move Quickly to Create Pathway for Follow-On Biologics

The Earth Times Online Newspaper (Free subscription) | 06/26/2008

WASHINGTON - Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the Congressional Budget Office (CBO) report issued today projecting cost savings from S. 1695, the Biologics Price Competition and Innovation Act of 2007:

CBO Savings Estimate for Follow-On Biologics

Thomas Net (Free subscription) | 06/25/2008

According to Jim Greenwood, BIO President and CEO, CBO report shows that developing pathway to review and approve follow-on biologics will result in cost savings to public and private purchasers of biologic products over 10 year period. Report finds that most savings will be obtained several years after follow-on pathway is established, reinforcing need for Congress to develop and pass responsible...

• CBO Savings Estimate for Follow-On Biologics Underscores Need for Congress to Move Quickly to Create Pathway for Follow-On Biologics - Business Wire
• CBO Savings Estimate for Follow-On Biologics Underscores Need for Congress to Move Quickly to Create Pathway for Follow-On Biologics - The Earth Times Online Newspaper

CBO Savings Estimate for Follow-On Biologics Underscores Need for Congress to Move Quickly to Create Pathway for Follow-On Biologics

Business Wire (Free subscription) | 06/26/2008

WASHINGTON--(BUSINESS WIRE)--Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood released the following statement regarding the Congressional Budget Office (CBO) report

Setting Aside the Renewable Fuel Standard Will Not Reduce Corn Prices

Thomas Net (Free subscription) | 06/24/2008

The Biotechnology Industry Organization (BIO) submitted comments to the U.S. EPA opposing Texas Gov. Rick Perry's request for a waiver of 50% of the Renewable Fuel Standard (RFS) mandate for production of ethanol from grain. According to BIO President and CEO Jim Greenwood, abandoning the RFS would send a signal to the market that could undercut ongoing research and development in biotechnology...

BIO Announces Future BIO International Convention Venues

Business Wire (Free subscription) | 06/20/2008

... community and drive further biotech investment throughout the Southeastern United States,” said Jim Greenwood, president and CEO of BIO, producer of the International Convention. “Our Convention has grown from an intimate industry gathering to a major global event, with more than one-third international attendance, including the most prominent industry leaders and public officials from around...

Biotechnology -- Fuel, Food and Medicine

The Earth Times Online Newspaper (Free subscription) | 06/20/2008

... developing disease and cold resistant-crops were some of the major topics under discussion. Jim Greenwood, President and CEO of the Biotechnology Industry Organization, calls biotechnology scientists "perpetual optimists." "We refuse," he says, "to accept that there is nothing we can do. We envision a world free of disease, free of hunger, and free of pollution." BIO represents 1,200 biotechnology...

• DWJ Television: Biotechnology -- Fuel, Food and Medicine - Market Wire - Media and Entertainment: Television

Incentives to Develop Medicines for Neglected Diseases Highlighted at 2008 BIO International Convention

The Earth Times Online Newspaper (Free subscription) | 06/18/2008

... promise for producing medicines that will ultimately alleviate suffering and save lives,” said Jim Greenwood, BIO president and CEO. “By analyzing the advantages and challenges of the various proposed incentives, we can engage in a discussion that will ultimately lead to market-based changes.”The paper, titled, “Ideas to Encourage Innovation for Diseases without a Market,” lays out incentives...

Press Conference on the Orphan Drug Act: 25 Years of Innovation

Red Orbit (Free subscription) | 06/04/2008

... patient, advocacy community, corporate, policymaker and government agency. Who: Speakers include: Jim Greenwood, BIO President and CEO Sen. Orrin Hatch (R-UT), original cosponsor of the Act (videotaped comments) Rep. Henry Waxman (D-CA), original cosponsor of the Act (videotaped comments) Diane Dormand, National Organization for Rare Disorders, Inc. Hillary and Kelly Lamoree (Cystic Fibrosis...

• Press Conference on the Orphan Drug Act: 25 Years of Innovation - EuroInvestor.co.uk

Press Conference on the Orphan Drug Act: 25 Years of Innovation

EuroInvestor.co.uk (Free subscription) | 06/04/2008

... patient, advocacy community, corporate, policymaker and government agency. Who: Speakers include: Jim Greenwood, BIO President and CEO Sen. Orrin Hatch (R-UT), original cosponsor of the Act (videotaped comments) Rep. Henry Waxman (D-CA), original cosponsor of the Act (videotaped comments) Diane Dormand, National Organization for Rare Disorders, Inc. Hillary and Kelly Lamoree (Cystic Fibrosis...